Currency In USD
| Previous Close | 1.72 |
| Open | 1.75 |
| Day High | 1.78 |
| Day Low | 1.7 |
| 52-Week High | 4.34 |
| 52-Week Low | 1.53 |
| Volume | 381,288 |
| Average Volume | 508,749 |
| Market Cap | 72.94M |
| PE | -3.42 |
| EPS | -0.5 |
| Moving Average 50 Days | 1.83 |
| Moving Average 200 Days | 2.02 |
| Change | -0.01 |
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
Results to be discussed in KOL event today at 10 a.m. ETBETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development